ARTICLE | Company News

Cipher, Edesa Biotech deal

June 27, 2016 7:00 AM UTC

Cipher granted Edesa rights to ASF-1096 to treat anorectal disorders. Cipher retains rights to dermatological indications. ASF-1096, a 0.5% cream formulation of the R-enantiomer of salbutamol (albuterol), has completed Phase II testing to treat discoid lupus erythematosus (DLE). ASF-1096 has Orphan Drug designation in the EU to treat cutaneous lupus erythematosus. ...